Poliovac

Active immunization of infants (as young as 6 wk), childn & adults for prevention of poliomyelitis caused by poliovirus types 1, 2 & 3.

IM/SC Childn Primary series: Three 0.5-mL doses at min interval of 4 wk. IPV-only schedule Administer primary series beginning at 2 mth. If primary series begins earlier (eg, w/ 6, 10 & 14-wk schedule), give booster dose after a ≥6 mth interval (for 4-dose schedule). Vaccination w/ OPV + IPV OPV birth dose (0 dose) followed by primary series of 3 OPV & at least 1 IPV dose (given from 14 wk & can be co-administered w/ an OPV dose). The primary series can be administered at 6, 10 & 14 wk (OPV1, OPV2, OPV3 + IPV) or at 2, 4 & 6 mth (OPV1, OPV2 + IPV, OPV3 or OPV1, OPV 2, OPV3 + IPV). Sequential IPV-OPV schedule Give IPV at 2 mth (eg, a 3-dose IPV-OPV-OPV schedule) or at 2 mth & 3-4 mth (eg, a 4-dose IPV-IPV-OPV-OPV schedule) followed by at least 2 OPV doses, w/ each dose in the primary series separated by 4-8 wk depending on risk of exposure in early childhood. Use w/ other vaccine May administer 3rd IPV dose if given between 15-18 mth w/ MMR vaccine &/or other vaccine. Unvaccinated adult 2 doses given at 1-2 mth interval & 3rd dose given 6-12 mth later. If <3 mth but >2 mth are available before protection is needed, 3 IPV doses should be given at least 1 mth apart. If only 1 or 2 mth are available, 2 IPV doses should be given at least 1 mth apart. If <1 mth is available, a single IPV dose is recommended. Incompletely vaccinated adult at increased risk of exposure who have had at least 1 OPV dose, fewer than 3 conventional IPV doses or combination of conventional IPV or OPV totaling fewer than 3 doses At least 1 IPV dose. Completely vaccinated adult at increased risk of exposure who have previously completed a primary series w/ 1 or a combination of polio vaccine 1 IPV dose.

Hypersensitivity to vaccine including 2-phenoxyethanol & formaldehyde. Defer vaccination of persons w/ acute, febrile illness until after recovery.

Allergic reactions may occur in persons sensitive to neomycin, streptomycin, polymyxin B, 2-phenoxyethanol & formaldehyde. Not to be administered IV. Immunogenicity in individuals receiving Ig. Patients w/ altered immune state. Guillain-Barré syndrome. Pregnancy & lactation. Systemic & local adverse reactions in infants receiving IPV concomitantly at separate sites or combined w/ DTP. Infants <6 wk.

Inj site pain, erythema, induration; moderate transient fever.

Adequate immunologic response may not be obtained in persons receiving immunosuppressive therapy.

Vaccines, Antisera & Immunologicals

J07BF03 - poliomyelitis, trivalent, inactivated, whole virus ; Belongs to the class of poliomyelitis viral vaccines.

Rx